News

Eli Lilly and Company (LLY) Releases Q2 2025 Results

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Eli Lilly: Don't Bet Against This Biotech Powerhouse

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, Pfizer in focus

Discover key highlights in healthcare stocks, including UnitedHealth's surge after a Buffett stake, Eli Lilly lawsuits, Trump pharma tariffs & Bayer's ...

This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

3 Fantastic Growth Stocks to Buy in August

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

1 Beaten-Down Stock That Could Soar by the End of the Year

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.